Led by Professor Jacob George, the Storr Liver Centre (SLC) conducts comprehensive research from bench to bedside to understand and treat liver disease and liver cancer. Focusing on conditions such as viral hepatitis, fatty liver disease, liver fibrosis, and liver cancer, SLC uses advanced molecular and cell biology techniques and animal models to drive clinical advancements. Key research areas include liver cancer progression, hepatitis B and C treatment, liver injury mechanisms, immunology, and fibrosis. The Centre is pioneering therapies like pluripotent stem cells for liver replacement, targeting cancer stem cells with nanomedicine, and developing drugs to cure hepatitis B. Collaborating with global research institutes and consumer groups, SLC ensures its work is impactful and aligned with community health needs.
Our research focus
- Liver: cancer development, growth and progression
- Hepatitis C and B virology and treatment
- Fatty liver disease
- Liver immunology
- Role of host genetics to liver disease progression and the outcomes of therapy
- The molecular and cellular basis of liver fibrosis
- Gene regulation pertaining to drug handling by the liver.
Research groups within this centre
GROUP HEADS
GROUP MEMBERS
GROUP HEADS
GROUP MEMBERS
GROUP HEADS
GROUP MEMBERS
GROUP HEADS
GROUP MEMBERS
GROUP HEADS
GROUP MEMBERS
Recent achievements
The Storr Liver Centre has enjoyed grant success in the field of precision medicine with a total of 2 investigator grants, 2 ideas grants, a NHMRC clinical trials and cohort studies grant on spatial transcriptomics for liver cancer and a NSW translational research grant on liver cancer to create a statewide clinical consortium.
These initiatives form the genesis of collaboration that in future will enhance opportunities for knowledge gain and further grant funding. However, our grant success and our collaborative links also bring with the fore, highly novel questions that if answered, can lead to the next generation of grants and treatments that will truly transform patient care for those with liver cancer.